Finding the causes of disease - by building the proteomics tools that reveal them.

Our Mission

Every cell in your body runs on proteins. Their dysfunction leads to disease. At Parallel Squared Technology Institute, we find these dysfunctions: To find the causes of disease, we build and use tools that rapidly detect and measure the most important molecular actors in health and disease: proteins. Our key developments improve how fast we can analyze both samples and proteins at the same time, speeding up research progress. That's why "Parallel Squared" is in the name - it reflects this dual parallelization, with many samples and many proteins being analyzed at once.

Why it Matters

• Measuring proteins more rapidly allows understanding of targeted diseases faster: Alzheimer's, autoimmune disorders, and various cancers.
• We exist to drive a massive scaling of research technology - 100x to 1000x increases
• We make our innovations available as public goods and accessible resources

Our Team & Environment

• PTI brings together scientists, engineers, and computational experts who rarely have the opportunity to work so closely together to organize around a central mission
• As a Focused Research Organization, we’re a nonprofit that runs like a startup
• We take pride in setting high standards: scientifically rigorous, intentionally interdisciplinary, and the ambition to better understand proteins and their critical role in health and disease
• Our progress is made possible by our generous funders and our excellent partners. They enable the development of new protocols and methods for sample preparation of brain tissue and immune cells, the analysis of these single cells, and the distribution of our findings to the broader community. We thank them for their continuous support.

Our Technology Approach

Combining methods to multiply the number of processed samples while simultaneously increasing the number of identified proteins is called ‘multiplexing’. With PTI’s multiplexing approach, researchers can run and analyze more biological samples smarter and faster, unlocking the next frontier in scientific breakthroughs across the biomedical spectrum.

plexDIA: A multiplexing approach that triples throughput even from tiny low-input samples while maintaining accuracy.

PSMtag: A next‑generation chemical tag that supports 9‑plexDIA to improve protein sequencing and enable the analysis of over 1,000 samples daily.

JMod: Joint modeling of protein fragments to boost multiplexing efficiency.

timePlex: Time-encoded sample multiplexing for faster, deeper analysis of proteins.

Biology in Action

Our biology and technology research move together at PTI: each multiplexing advance is built to answer real questions about how disease begins at the molecular level. We’re applying these tools to investigate neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease, in search of the protein pathologies that have evaded detection until now.

Now & Next

PTI’s vision encompasses the creation, optimization, and dissemination of technologies for researchers to rapidly and accurately analyze biological samples in bulk and at the single-cell level. We are already hard at work to make the next generation of research findings available to the public, diving deeper into the proteins of diverse immune cells and Alzheimer’s Disease neurons. As we continue to scale projects and collaborations, interested partners and funders are invited to contact us.